by barry101 | Jul 8, 2022 | Press Releases
– Preliminary results of second cohort in the first-in-human Phase 1a allow Company to proceed to 32 mg/kg dose of WP1122 in third cohort toward establishing maximum tolerated dose (MTD) — Multiple ascending dose (MAD) cohort to commence after completion...
by barry101 | Jun 16, 2022 | Press Releases
– Preliminary results of first cohort in the first-in-human Phase 1a allows Company to proceed to 16 mg/kg dose of WP1122 in second cohort toward establishing maximum tolerated dose (MTD) – – Multiple ascending dose (MAD) cohort to commence after...
by barry101 | May 26, 2022 | Press Releases
– Single ascending dose (SAD) cohort of first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 and establish maximum tolerated dose – – Multiple ascending dose (MAD) cohort to commence after completion of at least 3 SAD...
by barry101 | May 19, 2022 | Press Releases
HOUSTON, May 19, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | May 12, 2022 | Press Releases
– Positive advancements, encouraging preclinical and clinical data, and development activity in all three core technologies – – Multiple key clinical and regulatory milestones expected throughout 2022 – – Company has sufficient capital to...
by barry101 | May 10, 2022 | Press Releases
– Dosing for first-in-human Phase 1a study to evaluate safety and pharmacokinetics of WP1122 in healthy volunteers and establish maximum tolerated dose expected to commence imminently – HOUSTON, May 10, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX)...
